58.80
2.69 (4.79%)
| Penutupan Terdahulu | 56.11 |
| Buka | 55.79 |
| Jumlah Dagangan | 993,851 |
| Purata Dagangan (3B) | 1,053,539 |
| Modal Pasaran | 4,858,308,096 |
| Harga / Jualan (P/S) | 5.22 |
| Harga / Buku (P/B) | 4.53 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2026 |
| Margin Operasi (TTM) | -81,161.54% |
| EPS Cair (TTM) | -1.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -90.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.15% |
| Nisbah Semasa (MRQ) | 30.97 |
| Aliran Tunai Operasi (OCF TTM) | -81.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -57.18 M |
| Pulangan Atas Aset (ROA TTM) | -12.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | CG Oncology, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.00 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.17% |
| % Dimiliki oleh Institusi | 105.34% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Foresite Capital Management Vi Llc | 31 Dec 2025 | 2,221,474 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 80.00 (HC Wainwright & Co., 36.05%) | Beli |
| Median | 73.00 (24.15%) | |
| Rendah | 70.00 (Piper Sandler, 19.05%) | Beli |
| 70.00 (Wedbush, 19.05%) | Beli | |
| Purata | 73.60 (25.17%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 53.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Feb 2026 | 80.00 (36.05%) | Beli | 58.80 |
| Truist Securities | 10 Feb 2026 | 75.00 (27.55%) | Beli | 53.09 |
| 12 Jan 2026 | 66.00 (12.24%) | Beli | 53.72 | |
| RBC Capital | 21 Jan 2026 | 73.00 (24.15%) | Beli | 57.13 |
| Piper Sandler | 16 Jan 2026 | 70.00 (19.05%) | Beli | 54.73 |
| Wedbush | 11 Dec 2025 | 70.00 (19.05%) | Beli | 41.61 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 09 Jan 2026 | Pengumuman | CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC |
| 06 Jan 2026 | Pengumuman | CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 18 Dec 2025 | Pengumuman | SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award |
| 05 Dec 2025 | Pengumuman | New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |